Background: Rituximab has dramatic impact on outcome of patients with diffuse large B-cell lymphoma (DLBCL), especially nongerminal center (non-GC) type. A low absolute lymphocyte count (ALC) before rituximab, cyclophosphamide, vincristine, adriamycin, and prednisone (R-CHOP) therapy as a surrogate marker of immune status is associated with poor clinical outcome in DLBCL. Therefore, we hypothesized that low ALC before R-CHOP would have effect on the survival in non-GC type.
introduction Diffuse large B-cell lymphoma (DLBCL) is divided into germinal center (GC) and nongerminal center (non-GC) types using immunohistochemistry [1] . It has been shown that chemotherapy-treated patients with the GC type have a significantly better outcome compared with patients with the non-GC type [1] [2] [3] . However, addition of rituximab to chemotherapy improves the outcome of DLBCL patients of all ages and risk groups [4, 5] , which indicated that rituximab eliminates the adverse impact of the non-GC type on survival. Therefore, the cell-of-origin appeared not to predict the outcome for immunochemotherapy-treated DLBCL.
The absolute lymphocyte count (ALC) was important predicting survival of DLBCL patients with cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) therapy [6, 7] . Recent studies showed for low ALC before rituximab, cyclophosphamide, vincristine, adriamycin, and prednisone (R-CHOP) therapy predicts a poor response rate and clinical outcomes in DLBCL patients [8] [9] [10] . Therefore, a low ALC before rituximab in DLBCL patients was indicated to counteract the effect of R-CHOP therapy, especially in the non-GC type.
The objective of the present study was to investigate whether the ALC before therapy is associated with survival in DLBCL patients on the basis of cell-of-origin.
patients and methods patients
One hundred and thirty-six DLBCL patients were retrospectively analyzed, who were treated at Pusan National University Hospital from September 2003 to January 2008. The median follow-up for immunochemotherapytreated patients was 36 months. The median age was 61 years (range 20-79 years) and the male-to-female ratio was 1.125 : 1 (Table 1) .
Patients were included if they had primary nodal localization, were available for clinical follow-up, had a suitable histological inclusion evaluation, and also had a de novo DLBCL histotype. Patients were excluded if they presented with masses of uncertain nodal origin (mediastinum or central nervous system involvement), DLBCL secondary to low-grade original article non-Hodgkin's lymphoma, or previous treatment including autologous stem-cell transplantation. Furthermore, patients were excluded if they had clinically relevant chronic liver disease or antibodies against human immunodeficiency virus and evidence of infection at the time of diagnosis. The stage of disease was evaluated according to the Ann Arbor staging system. All patients had undergone a staging investigation, including a physical examination, blood and serum analysis, bone marrow (BM) aspiration and biopsy, and computed tomography of the neck, chest, abdomen, and pelvis. The following clinical and laboratory data were available at the time of diagnosis: age, gender, serum lactate dehydrogenase (LDH) level, performance status, B symptoms, clinical stage, and BM involvement. The study was reviewed and approved by our institutional review board, and a written statement of informed consent was obtained from each patient.
treatment
All patients were scheduled to receive six to eight full cycles of R-CHOP-21 therapy by Coiffier et al. [11] Patients in whom the lymphoma recurred despite first-line therapy were treated with the etoposide, methylprednisolone, cytarabine and cisplatin regimen.
immunohistochemistry staining
Sections from formalin-fixed paraffin blocks were transferred to poly-Llysine-coated glass slides and air-dried overnight at 37°C. They were then dewaxed in xylene (three changes), rehydrated in a graded series of decreasing ethanol concentrations, and rinsed in Tris-buffered saline (pH 7.4). Endogenous peroxidase activity was inactivated with 5% hydrogen peroxide in methanol for 15 min at 37°C. Heat-induced antigen retrieval was carried out for 45 min in Tris-EDTA buffer (pH 8) for all four antibodies in a pressure cooker at 95°C. Following, primary antibodies were incubated for 1 h at room temperature: BCL-6 (clone PG-B6P, working dilution 1 : 40; Dako, Copenhagen, Denmark), CD10 (clone 56C6, working dilution 1 : 200; Lab Vision, CA), and MUM-1 (clone MUM1p, working dilution 1 : 50; Dako). The antibody in an EnvisionTM ChemTM Detection Kit (Dako, Carpinteria, CA) was used for the secondary antibody at room temperature for 30 min; 3,3#-diaminobenzidine was used as a chromogen and then Mayer's hematoxylin counterstain was applied.
Immunohistochemical reactions were evaluated semiquantitatively by considering the percentage of positive tumor cells in the neoplastic tissue. In agreement with Hans et al. [1] , the optimal cut-off value was considered to be 30% for CD10, Bcl-6, and MUM-1. The samples were analyzed independently by two pathologists and disagreements resolved by a joint review on a multihead microscope.
GC and non-GC types were defined on the basis of CD10, Bcl-6, and MUM-1 staining according to algorithm developed by Hans et al. The GC type was defined as CD10+ or CD102/Bcl-6+/MUM-12. The non-GC type was defined as CD102/Bcl-62 or CD102/Bcl-6+/MUM-1+.
statistical analyses
The chi-square test was used to assess differences in the frequency of individual prognostic factors. Tumor responses were assessed after 6 or 8 cycles and were classified as a complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to International Workingshop Criteria. Progression-free survival (PFS) was calculated from the date of diagnosis to documented disease progression; observations were censored on the date the patient was last known to be alive, or for patients dying as a result of causes unrelated to lymphoma or treatment, the date of death. Overall survival (OS) was calculated from the date of diagnosis until death as a result of any cause or the date last known to be alive. PFS and OS were estimated by the Kaplan-Meier method and the differences were compared using a log-rank test. Statistical data processing was carried out with SPSS software for Macintosh (SPSS 14.0; Chicago, IL). A probability value <0.05 was considered statistically significant.
results

patient characteristics
One hundred and thirty-six patients with DLBCL were treated with R-CHOP from 2003 to 2007. Fifty-eight patients were in advanced stage (stages III and IV) and 74 patients had an elevated LDH status at the time of diagnosis. Seventy-six patients were >60 years of age and 20 subjects had an Eastern Cooperative Oncology Group performance status of more than two. Bulky disease was present in 25 cases. The GC subtype was applied to 70 of 136 cases; the other 66 were of the non-GC subtype.
The ALC was measured just before R-CHOP therapy. Analysis of different cut-off levels between the 25% and 75% quartiles (0.24-3.28 · 10 9 /l) using the log-rank test determined that an ALC ‡1.0 · 10 9 /l as the cut-off point yielded the highest difference in OS and PFS. Thus, this cut-off level was used in statistical analysis. Eighty-six patients were included in the high ALC group ( ‡1.0 · 10 9 /l), whereas the other 50 patients were in the low ALC group (<1.0 · 10 9 /l). The overall response rate (ORR) was 90.4% (123 of 136 patients) with a CR of 83.8% (114 of 136 patients) and a PR of 6.6% (9 of 136 patients). The PFS and OS in the low international prognostic index (IPI) score patients were 82.9% and 86.6%, respectively, whereas the PFS and OS in the high IPI score patients were 61.1% and 64.8%, respectively (Table 1) . Table  1 ). The Kaplan-Meier estimate curves showed that the 3-year PFS and OS in the high ALC group were significantly higher compared with the low ALC group [PFS 82.6% versus 60.0%, P = 0.005 ( Figure 1A ) and OS 87.2% versus 62.0%, P = 0.001 ( Figure 1B) ].
The clinical outcome according to the GC type versus the non-GC type was also analyzed and shown in Figure 1C and D. The 3-year PFS and OS were comparable between the GC and non-GC types (PFS 80.0% versus 68.2%, P = 0.074; OS 82.9% versus 72.7%, P = 0.111) (Figure 1C and D) .
survival pattern according to ALC combined with immunophenotype
It was also determined whether ALC between GC and non-GC type DLBCL patients treated with R-CHOP would have a clinical importance. The prognostic value was compared among the four subgroups based upon the ALC level and GC or non-GC types (GC group with high ALC, GC group with low ALC, non-GC group with high ALC, and non-GC group with low ALC; Table 2 ). The baseline characteristics were well conserved. No significant difference was observed among the four subgroups in terms of age, gender, LDH level, stage, PFS, bulky disease, B symptoms, BM involvement, and IPI score.
A low ALC was associated with a lower PFS and OS compared with a high ALC in the non-GC group. However, the ALC did not predict the 3-year PFS and OS in the GC group. Comparing the above four groups, the PFS and OS in the low ALC and non-GC group were significantly lower than the other groups (P = 0.002 and P < 0.001, respectively; Figure 2 ).
multivariate analysis
To further investigate the prognostic value of the ALC in the GC or non-GC groups, Cox proportional hazards analyses were carried out for the non-GC group with low ALC and the other three subgroups. According to multivariate analysis, the non-GC group with low ALC was an independent factor Figure 1 . The clinical outcomes of patient groups according to ALC or immunophenotype; 3-year progression-free survival and overall survival of the high ALC group were higher than the low ALC group (A and B: P = 0.005 and P < 0.001, respectively). However, the survival of the GC group was comparable to the non-GC group (C and D: P = 0.074 and P = 0.111, respectively). ALC, absolute lymphocyte count; GC, germinal center; non-GC, nongerminal center.
original article Annals of Oncology predicting an unfavorable outcome when the IPI score was included in the multivariate analysis (Table 3) . We concluded that the non-GC type DLBCL patients with a low ALC at diagnosis had a poorer prognosis than patients included in the other three groups.
discussion
Rituximab is a chimeric anti-CD20 mAb with murine variable regions and human IgG and kappa constant regions. Rituximab has had a significant impact on treatment and outcome of patients with DLBCL; however, the response to rituximab is incomplete, and the minority of patients may not respond to initial treatment with rituximab. Therefore, an understanding of multiple mechanisms involved in rituximab-induced cytotoxicity is important. Several immunologic-related mechanisms have been attributed to rituximab, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity, direct apoptotic signaling, and a possible vaccine effect [12] .
Recent studies showed that a low ALC at diagnosis of DLBCL is associated with poor outcome in patients treated with CHOP or R-CHOP [8] [9] [10] . These results demonstrated that the ALC at diagnosis, as a surrogate marker of host immune status, affects the therapeutic efficacy (especially with R-CHOP) in DLBCL. The present study also showed that a low ALC at diagnosis in The clinical outcome of the patient groups according to immunophenotype and ALC; 3-year PFS and OS between GC type with high ALC and GC type with low ALC was not significantly different (P = 0.548 and P = 0.300, respectively). The PFS and OS between GC type with high ALC and non-GC type with high ALC were also comparable (P = 0.559 and P = 0.921, respectively). Therefore, the PFS and OS in the non-GC group with low ALC were significantly lower than the other groups (P = 0.002 and P < 0.001, respectively). PFS, progression-free survival; OS, overall survival; ALC, absolute lymphocyte count; GC, germinal center; non-GC, nongerminal center.
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patients with DLBCL treated with R-CHOP therapy was associated with poor prognosis. However, another study showed conflicting results [13] ; specifically, it was found that only a low absolute value of natural killer (NK) cells, and not the ALC, is a negative prognostic marker for event-free survival. These contrasting results may be due to heterogenous patient selection and diversity in treatment. DLBCL is a heterogenous disease, comprised of GC and non-GC types. The addition of rituximab to chemotherapy improves survival in DLBCL patients. However, recent studies have shown that the influence of rituximab on survival is significant in the immunohistochemically non-GC type but not the GC type [4, 14] . As indicated by studies in cell culture conditions, rituximab may suppress the constitutively active nuclear factor jB pathway in the non-GC type DLBCL or perturb Bcl-2-related antiapoptotic proteins, thereby leading to increased sensitivity of lymphoma cells to chemotherapy [15] [16] [17] . In the present study, the PFS and OS of these two immunophenotypes were also comparable. However, considering the adverse effects of the ALC according to immunophenotype in other risk-comparable settings, a low ALC was significantly associated with the non-GC type compared with the GC type. This result reflects the importance of ADCC by enhancing NK cells as an important effector cell after binding of rituximab to CD20-positive lymphoma cells, especially the non-GC type. These findings support the concept that ALC at diagnosis in non-GC type DLBCL treated with R-CHOP might be an important predictive factor of survival.
In conclusion, we indicate that a low ALC at diagnosis might counteract the beneficial effect of rituximab, especially in non-GC type DLBCL patients, although the drug is well known to overcome the poor outcome of non-GC type in a conventional chemotherapy setting. A well-designed prospective study, including the T/NK cell subset, might provide further information regarding this observation. disclosure 
